Literature DB >> 11902121

Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesencephalic neurones in primary culture.

Sophie Callier1, Maryvonne Le Saux, Anne-Marie Lhiaubet, Thérèse Di Paolo, William Rostène, Didier Pelaprat.   

Abstract

Recent findings suggest that gonadal steroid hormones are neuroprotective and may provide clinical benefits in delaying the development of Parkinson's disease. In this report we investigated the ability of oestradiol to protect mesencephalic dopaminergic neurones cultured in serum-free or serum-supplemented medium from toxicity induced by 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion (MPP+). The efficiency of both toxins and oestradiol was evaluated by tyrosine hydroxylase (TH) immunocytochemistry, [3H]dopamine ([3H]DA) uptake, length of dopaminergic processes and lactate dehydrogenase (LDH) release measurement. In cultures grown in serum-supplemented medium, a 2-h pre-treatment with high concentrations (10-100 microM) of 17beta-oestradiol or 17alpha-oestradiol, the stereoisomer with weak oestrogenic activity, protected both dopaminergic and non-dopaminergic neurones from toxicity induced by 6-hydroxydopamine (6-OHDA; 40 or 100 microM) and by the high MPP+ concentrations (50 microM) necessary to obtain significant neuronal death under those culture conditions. At these concentrations, MPP+ was no longer selective for dopaminergic neurones but affected all cells present in the culture. In contrast, the hormonal treatments did not protect against selective degeneration of dopaminergic neurones induced by lower MPP+ concentrations (below 10 microM), related to inhibition of complex I of respiratory chain. In cultures grown in serum-free medium, oestradiol concentrations higher than 1 microM induced neuronal degeneration and no protection against 6-OHDA or MPP+ toxicity was observed at lower concentrations of the steroid. The neuroprotective effects of 17alpha- or 17beta-oestradiol evidenced in this model might be due to the antioxidant properties of these compounds. However, other non-genomic effects of the steroids cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11902121     DOI: 10.1046/j.0022-3042.2001.00693.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?

Authors:  Rachel Saunders-Pullman
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 2.  The Role of Estrogen in Brain and Cognitive Aging.

Authors:  Jason K Russell; Carrie K Jones; Paul A Newhouse
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

3.  Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Begoña Villar-Cheda; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Maria J Guerra
Journal:  Aging Dis       Date:  2011-04-20       Impact factor: 6.745

Review 4.  Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.

Authors:  Glenda E Gillies; Simon McArthur
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

5.  Topological and chronological features of the impairment of glucose metabolism induced by 1-methyl-4-phenylpyridinium ion (MPP+) in rat brain slices.

Authors:  N Maruoka; T Murata; N Omata; Y Takashima; Y Fujibayashi; Y Wada
Journal:  J Neural Transm (Vienna)       Date:  2007-04-16       Impact factor: 3.575

6.  Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon.

Authors:  Mona Bains; Joanne C Cousins; James L Roberts
Journal:  Exp Neurol       Date:  2007-01-25       Impact factor: 5.330

7.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 8.  Estrogens and Parkinson disease: novel approach for neuroprotection.

Authors:  Hideyuki Sawada; Shun Shimohama
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

9.  Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle.

Authors:  Anete Curte Ferraz; Francesca Matheussi; Raphael Escorsim Szawka; Vanessa Rizelio; Ana Márcia Delattre; Paula Rigon; Erica do Espírito Santo Hermel; Léder Leal Xavier; Matilde Achaval; Janete A Anselmo-Franci
Journal:  Neurochem Res       Date:  2008-02-09       Impact factor: 3.996

Review 10.  Brain renin-angiotensin system and dopaminergic cell vulnerability.

Authors:  Jose L Labandeira-García; Pablo Garrido-Gil; Jannette Rodriguez-Pallares; Rita Valenzuela; Ana Borrajo; Ana I Rodríguez-Perez
Journal:  Front Neuroanat       Date:  2014-07-08       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.